Physician profile
Ashley E Frith
NPI 1730352014
$14,497.24
in general payments reported to CMS, 2019-2025
18 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.91 · 2021: $2,332 · 2022: $2,195 · 2023: $2,011 · 2024: $4,951 · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,743 · Food and Beverage: $2,632 · Travel and Lodging: $1,488 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,742.50 |
| Food and Beverage | $2,632.30 |
| Travel and Lodging | $1,487.60 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,320.42 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $2,500.54 | 2023-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,312.50 | 2023 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $1,198.07 | 2022-2025 | Enhertu |
| Lilly USA, LLC | $262.40 | 2024-2025 | Verzenio, Jaypirca |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Cti Biopharma Corp. | $122.78 | 2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2025 | Reblozyl |
| Tempus Ai, INC | $118.27 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.09 | 2023 | |
| Stemline Therapeutics INC. | $100.13 | 2025 | Orserdu |
| Merck Sharp & Dohme LLC | $84.34 | 2019-2025 | Keytruda, Lynparza |
| Sumitomo Pharma America, INC. | $23.30 | 2025 | Orgovyx |
| Emd Serono, INC. | $16.58 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Frith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.